The Ben Towne Center’s mission is to translate scientific discoveries into innovative therapies that cure childhood cancer with minimal side effects and improve survivors’ quality of life.
We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.
Our clinical trials are helping children with acute lymphoblastic leukemia achieve complete remission.
You are helping us create a future where pediatric cancer treatment is less toxic and far less harmful
Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.
You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.
Our researchers have started the first round of clinical trials exploring a potential cure.
Help us answer questions about childhood health and illness, and help other children in the future. Learn more.
Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.
Please visit Seattle Children’s careers page to learn about current openings.
For information about potential opportunities in the Ben Towne Center, email us.
Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults whose leukemia escapes CD19 CAR T-cell therapy – 7.26.2017 – MarketWatch After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse. Researchers have now opened a phase 1 clinical trial, PLAT-04, for children and young adults with relapsed or refractory CD22-positive ALL. Dr. Corinne Summers, an oncologist at Seattle Children's and the lead investigator of the PLAT-04 trial, and a research team led by Dr. Mike Jensen at the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute, are opening PLAT-04 after discovering that of the patients who relapsed in the PLAT-02 trial, approximately 40 percent of them relapsed with a leukemia that evolved to circumvent the CAR T cells that were reprogrammed to detect and destroy cancer. The T-cell immunotherapy trials at Seattle Children's are funded in part by Strong Against Cancer.
Kymab announces clinical update on its promising new antibody KY1005 for treatment of autoimmune diseases – 7.31.2017 – Yahoo! Finance Kymab, a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs, announced that KY1005, its novel human antibody therapeutic, has successfully completed dosing of the 24th subject in its first clinical study. KY1005 has already shown outstanding preclinical results in a project led by Dr. Leslie Kean, associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's Research Institute, published in a poster presentation at the American Society of Hematology Annual Meeting.
Seattle Children’s aims to outsmart cancer in a new trial – KING-TV – 8.08.2017 Seattle Children's Ben Towne Center for Childhood Cancer Research is actively fighting pediatric leukemia by harvesting and reprogramming a child's own T cells and using the immune system to fight cancer. Those T cells are collected from the patient and re-engineered into targeted cancer-killing CAR-T cells. “We've achieved phenomenal remission rates. With that therapy more than 90% of our kids have gotten into remission. These are kids that were resistant to traditional chemotherapy,” said Seattle Children’s oncologist Dr. Colleen Annesley.
Email the BTCCCR
1100 Olive Way, Suite 100
Seattle, WA 98101
PO Box 5371
Seattle, WA 98145-5005